Pink Eye (Conjunctivitis) Study

If you do have pink eye, you may be eligible to participate in this research study. Pink eye is an infection of the eye that can cause eye redness, tearing, and eyes feeling sore, gritty, or irritated. Pink eye spreads easily between people and to the other eye of the same person.

The study will evaluate an investigational drug in the form of eye drops intended to treat pink eye. Both adults and children are eligible to participate.

Volunteers who take part in the study will receive all study-related care and study drug at no cost. Volunteers may also be reimbursed for travel expenses.

No health insurance is required to participate.

To participate you must:

  • Be experiencing signs/symptoms of pink eye for no more than the past 4 days.
  • Be interested in taking part in a research study for up to 13 days.
  • Be willing to travel to the study center for appointments.

Find Out If You Pre-Qualify

Frequently Asked Questions

The type of studies we conduct at Vision Consultants and Surgeons are in their last step to obtain FDA-approval for commercial availability and comply with the FDA guidelines for safe research. This means the study medications have already passed extensive testing for safety and efficacy in highly controlled environments.
As with any medical treatment, participation in a clinical trial offers benefits and risks. Researchers conducting these trials will clearly explain the potential benefits and risks so you can feel confident about making the best decision. Participants always reserve the right to end their participation at any time, even if the study is not complete.
All clinical trials must be approved by an Institutional Review Board (IRB). An IRB is made up of physicians, researchers and members of the local community. Its role is to make sure that the study is ethical and the rights and welfare of participants are protected. This includes ensuring high safety standards and processes are followed, and that risks are minimized and reasonable in relation to potential benefits.
The Food and Drug Administration (FDA) also plays an important role in the clinical trials process, ensuring the safety of participants, qualifications of researchers and the safety and efficacy of the studies.
It’s always best to discuss with your physician whether a clinical trial is right for you.

It’s important for individuals of varied races, ethnicities, ages, gender and sexual orientation to participate in clinical trials. We know that some medicines impact people differently. For example, certain blood pressure medications are less effective in African Americans than other races. Inclusion of participants from diverse backgrounds furthers research and helps find better ways to fight diseases that disproportionately impact these populations.
The current clinical trial system faces many challenges in recruiting and retaining eligible participants. According to the Center for Information and Study on Clinical Research Participation, only 6% of clinical trials are completed on time and 50% of clinical research sites enroll one or no patients in their study. Delays in trial completion lead to delays in regulatory review and approval process- which ultimately delays patient access to new, potentially life-saving medicines.

Participation in a clinical trial often provides patients access to potential new treatments and to expert health care at leading institutions. By participating in a clinical trial, you play an active role in your health and the health of others by contributing to scientific knowledge that may lead to potential new medical treatments for future patients.

Clinical trials are conducted by physicians, investigators and researchers at various organizations including local research institutions, hospitals and universities.

Clinical trials are scientific studies in which researchers evaluate potential new treatments by monitoring their effects on people. It is important to test how individuals react to potential new therapies in order to gauge their safety and effectiveness. Even if at the end of the research period a therapy is not approved for lack of safety or effectiveness, clinical trials contribute greatly to the overall base of knowledge, and may help researchers develop new treatments in the future.

The FAQ content was obtained from the I’m In Campaign founded by the Pharmaceutical Research and Manufacturers of America (PhRMA) and the National Minority Quality Forum (NMQF)

Ophthalmic Research Coordinator

Joanna Kuttothara is our lead ophthalmic research coordinator. She is dedicated to providing patients with access to cutting-edge treatments through clinical trials. She is known for always putting patients first and focusing on how patients benefit from participating in clinical trials.

She completed her Bachelor of Arts Degree from the University of Rochester in Rochester, New York and is a graduate of the Escuela de Medicina de la Universidad Panamericana  in Mexico City, Mexico. She is fully bilingual in Spanish and English.

Contact Joanna directly:  202-239-0777